Cardiovascular and Metabolic diseases

Following the science to help people maintain and improve cardiovascular and metabolic health

An enduring, bold ambition to break through conventional thinking in cardiovascular and metabolic health

AstraZeneca has a patient-centric approach to disease treatment, so we are tackling multiple risk factors by uniting our cardiovascular (CV), metabolic and chronic kidney disease (CKD) disease areas into one integrated approach – cardiovascular and metabolic disease (CVMD).

This approach means we look at the CVMD patient as a whole, rather than by disease area, because we know that cardiovascular disease (CVD) is a well-known consequence of diabetes and CKD. Each of our focus areas seek to further reduce cardiovascular morbidity and mortality, and organ damage by addressing multiple CV risk factors.

Read more

AstraZeneca has been driving CV innovation for more than 100 years. As we aim to break through conventional thinking by following what the science is telling us, we will:

  • continue to build our CV and diabetes portfolio to help a broader range of patients
  • focus on investigating the impact of treatment options on reducing CV events and death in a broad range of high-risk patients, beyond acute coronary syndromes (ACS)
  • shift the treatment paradigm of Type 2 diabetes to early combination therapy and accelerate achievement of treatment goals
  • develop new therapies for anaemia in people with CKD.

Our enduring goal is to push the boundaries of science to deliver life-changing medicines to the people who need them, and contribute to improved health for millions more people around the world.

Our focus on unmet needs

  • CVD

    Cardiovascular disease is responsible for 30% of all deaths globally, one in three deaths in the US and more than half of all deaths across Europe.

  • ACS

    Acute coronary syndromes, which include heart attack and unstable angina, are responsible for almost half of all deaths worldwide related to cardiovascular disease.

  • Diabetes

    Diabetes is a growing disease and an enormous global burden that is currently projected to affect more than 592 million people by the year 2035.

  • CKD

    Chronic kidney disease is a complex, debilitating condition that affects more than 70 million people worldwide and more than 20 million adults in the US.

What we're working on

As part of our commitment to CVMD, here you can find highlights of our key areas of focus.

Novel approach to chronic kidney disease (CKD) research addresses both its complications and underlying causes

We are investing in ground-breaking science to develop new therapies that will aggressively prevent, treat, manage and modify CKD.

Our pipeline

Our current pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.

Cardiovascular and Metabolic diseases (as at 27 April 2017)

Phase 1

Phase 1

  • AZD4831 heart failure with a preserved ejection fraction
  • AZD5718 CAD
  • AZD8601 cardiovascular
  • MEDI8111 trauma/bleeding

Phase 2

Phase 2

  • AZD4076 non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NASH)
  • MEDI0382 diabetes/obesity
  • MEDI4166 diabetes/cardiovascular
  • MEDI6012 ACS

Phase 3

Phase 3

  • Epanova severe hypertriglyceridaemia
  • Farxiga/Forxiga type-2 diabetes
  • ZS-9 (sodium-zirconium cyclosilicate) hyperkalaemia
  • roxadustat OLYMPUS ROCKIES anaemia in CKD/ESRD

LCM Projects

LCM Projects

  • Brilinta/Brilique HESTIA prevention of vaso-occlusive crises in paediatric patients with sickle cell disease
  • Brilinta/Brilique PEGASUS- TIMI 54 outcomes study in patients with prior myocardial infarction
  • Brilinta/Brilique THEMIS outcomes study in patients with type-2 diabetes and CAD, but without a previous history of MI or stroke
  • Bydureon EXSCEL type-2 diabetes outcomes study
  • Bydureon weekly autoinjector type-2 diabetes
  • Epanova STRENGTH outcomes study in statin-treated patients at high CV risk, with persistent hypertriglyceridemia plus low HDL-cholesterol
  • Farxiga/Forxiga effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure
  • Farxiga/Forxiga renal outcomes and cardiovascular mortality in patients with CKD
  • Farxiga/Forxiga type-1 diabetes
  • Farxiga/Forxiga DECLARE- TIMI 58 type-2 diabetes outcomes study
  • Kombiglyze XR/Komboglyze type-2 diabetes
  • Qtern (saxagliptin/dapagliflozin) type-2 diabetes
  • Xigduo XR/Xigduo type-2 diabetes

Our medicines

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.

  • Atacand, Atacand HCT, Atacand Plus candesartan cilexetil
  • Brilinta/Brilique ticagrelor
  • Bydureon exenatide
  • Byetta exenatide injection
  • Crestor rosuvastatin
  • Farxiga/Forxiga dapagliflozin
  • Kombiglyze XR saxagliptin and metformin XR
  • Komboglyze saxagliptin and metformin HCl
  • Onglyza saxagliptin
  • Plendil, Modip, Splendil, Munobal, Flodil felodipine
  • Seloken ZOK, Toprol-XL, Betaloc ZOK metoprolol succinate
  • Symlin pramlintide acetate
  • Tenormin, Tenormine, Prenormine, Atenol atenolol
  • Zestril lisinopril dihydrate
  • XIGDUO dapagliflozin and metformin HCI
  • XIGDUO XR dapagliflozin and metformin HCI extended-release

Searching for a cure for heart failure

Cardiac regeneration: can science help the heart heal itself?

We know the heart has the potential to heal itself, the question is how? By working together towards a shared goal, these scientists think they might have found the answer.
View story

Disease area resources

Other resources

ATLAS ID: 1026605.011                                                           
Date of next review: January 2018